Pharmaceutical companies are in a high‑stakes race to use artificial intelligence to compress clinical timelines and secure regulatory approvals before rivals do. After years of experimentation, AI is moving from pilot projects to the core of how trials are designed, run, and documented. The shift is reshaping everything from site selection to regulatory submissions, with the promise of cheaper development and faster access to new medicines.
The pressure is intense. The inflation‑adjusted cost of developing a new drug now doubles roughly every nine years, while pipelines grow more complex and payers more demanding. Drugmakers see AI as the only realistic way to bend that cost curve and to turn vast stores of clinical and real‑world data into decisions that regulators and investors will trust.
The new operating system for clinical development
Large pharmaceutical groups are treating AI not as a side project but as a new operating system for development. Companies such as Novartis are embedding machine learning into trial design, patient recruitment, and safety monitoring, while peers like Amgen are building internal platforms that connect discovery data with late‑stage outcomes. The goal is to replace fragmented, manual workflows with integrated models that can predict which protocols will recruit, which endpoints will read out, and which assets deserve scarce capital.
Industry strategists argue that 2026 marks an inflection point, with AI no longer an experiment but the backbone of decision-making across portfolios. One analysis projects that, if adopted at scale, AI could help reverse the trend of soaring costs and support a wave of new approvals by 2030. That vision depends on whether companies can standardize data, validate models, and convince regulators that algorithmic recommendations are as reliable as traditional expert judgment.
From protocol to patient: AI inside the trial engine
The most immediate gains are emerging in the unglamorous plumbing of clinical operations. AI tools are now scanning historical enrollment data and real‑world records to pick trial sites that actually recruit, rather than relying on habit or sales footprints. In one program, the typical four to six-week site selection process was compressed into a two-hour meeting after algorithms ranked locations by past performance and patient density, a shift described in detail in reporting on site selection. Similar models are being used to flag protocol criteria that would choke enrollment before the first patient is screened.
Vendors are also automating the most laborious parts of trial setup. One trend report highlights how AI‑powered protocol automation can generate consistent study designs across a program, harmonize endpoints, and pre‑check feasibility against historical data. Specialist firms promote tools that utilize LLM models to draft protocols, align them with regulatory templates, and accelerate study initiation. At the same time, operational teams are using AI to optimize visit schedules, reduce patient burden, and monitor adherence in near real time, turning trials into more adaptive, data‑rich systems rather than rigid, one‑off experiments.
Agentic AI and the automation of regulatory work
The race does not end when the last patient completes a visit. Drugmakers are now pointing AI at the mountain of documentation that stands between a positive trial and a marketable product. German radiopharmaceuticals firm ITM told Reuters it has built systems that convert long clinical study reports into U.S. Food and Drug Administration templates, cutting weeks of manual formatting. Other companies are experimenting with generative tools that assemble tables, figures, and narratives from structured data, then route them to human reviewers for scientific and legal checks.
Some of the most aggressive efforts focus on so‑called agentic AI, or AI that is autonomous and requires little human intervention. Analysts suggest that Agentic AI could increase clinical development productivity by about 40 percent by taking over low‑risk but high‑labor tasks such as data cleaning, consistency checks, and template population. One technical paper notes that AI agents can significantly reduce development timelines by automating these activities, provided that clear limits on autonomy and escalation paths are in place. Companies such as Takeda are already piloting systems that use generative models to assemble submission components, arguing that improved timelines could bring important therapies to patients more quickly.
Regulators, risk, and the battle for trust
Regulators are moving quickly to keep pace with this transformation. The U.S. Food and Drug Administration has created a dedicated program on artificial intelligence in drug development, signaling that AI‑generated or AI‑analyzed evidence will be accepted if it meets quality standards. The FDA and the European Medicines Agency have issued a joint statement that sets out ten principles for how AI should be designed, used, and managed when it generates or analyzes evidence in support of medicines in the European Union, a framework summarized in guidance on model behavior. Separate commentary notes that the agencies are using major investor conferences to underline their expectations and to respond to the burgeoning interest in this technology, as described in coverage of the joint AI guidance.
The FDA has also issued its first detailed guidance on how sponsors should document, validate, and monitor AI systems used in development, providing direction on lifecycle management and transparency. Industry groups are responding by publishing best practices on integrating generative tools into statistical programming and reporting, arguing that integrating these systems into traditional processes offers speed, accuracy, and scalability. At the same time, clinical technology leaders such as Lisa Moneymaker of Medidata describe 2026 as a turning point when AI must finally deliver measurable improvements in trial performance. Forecasts suggest that AI‑enabled clinical improvements could nearly double investigational new drug application success rates while cutting timelines, as highlighted in an analysis of success rates. Commentators on AI in pharma argue that this is the year AI becomes core infrastructure. In contrast, operational case studies on how drugmakers use AI to speed trials and filings show that the race for faster approvals is already well underway.